Development Outside the Territory. As between Kyowa Kirin and Reata, Reata shall be solely responsible and shall have sole discretion and control (at Reata’s sole cost and expense) for all non-clinical, clinical and other development or commercialization activities (including regulatory activities) with respect to Licensed Products outside the Territory. Reata, through the JSC, will keep Kyowa Kirin reasonably informed of all material events and developments, including any Adverse Events, occurring in the course of the non-clinical, clinical and other development activities for Licensed Products outside the Territory. Reata will consider recommendations that Kyowa Kirin may make to Reata regarding aspects of non-clinical and clinical trial and other development activities for Licensed Products outside the Territory that would be particularly helpful in obtaining Commercialization Regulatory Approval for Licensed Products within the Territory, provided, however, Reata shall be under no obligation to accept or act on any such recommendations, and Reata shall have the final decision-making authority with respect thereto. [***].
Development Outside the Territory. As between the Parties, and except as provided in Section 4.6, Versartis shall be solely responsible and shall have sole discretion and control (at Versartis’ sole cost and expense) for all non-clinical, clinical, and other development and commercialization activities (including regulatory activities) with respect to Licensed Products in the Versartis Territory and, as between the Parties, the results of such activities shall be the sole property of Versartis. In the event that such development activities constitute Joint Development Work, Versartis shall reasonably consider, and where reasonably feasible use Commercially Reasonable Efforts to accommodate, any request by Teijin to arrange clinical trials outside the Territory as global studies (rather than local studies directed to a particular jurisdiction) which can be directly used to support Regulatory Approval in the Territory. [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Development Outside the Territory. Amgen shall have the sole right to manage and conduct the development of Dmab outside the Territory in all indications. The foregoing is without prejudice to Collaborator’s payment obligations pursuant to Section 8.8 (Development Cost Sharing).
Development Outside the Territory
